Role of chemokines in hepatocellular carcinoma (Review)

DONGDONG XUE1*, YA ZHENG2*, JUNYE WEN1, JINGZHAO HAN1, HONGFANG TUO1, YIFAN LIU1 and YANHUI PENG1

1Department of Hepatobiliary Surgery, Hebei General Hospital, Shijiazhuang, Hebei 050051; 2Medical Center Laboratory, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai 200065, P.R. China

Received September 5, 2020; Accepted December 4, 2020

DOI: 10.3892/or.2020.7906

Abstract. Hepatocellular carcinoma (HCC) is a prevalent malignant tumor worldwide, with an unsatisfactory prognosis, although treatments are improving. One of the main challenges for the treatment of HCC is the prevention or management of recurrence and metastasis of HCC. It has been found that chemokines and their receptors serve a pivotal role in HCC progression. In the present review, the literature on the multifactorial roles of exosomes in HCC from PubMed, Cochrane library and Embase were obtained, with a specific focus on the functions and mechanisms of chemokines in HCC. To date, >50 chemokines have been found, which can be divided into four families: CXC, CX3C, CC and XC, according to the different positions of the conserved N-terminal cysteine residues. Chemokines are involved in the inflammatory response, tumor immune response, proliferation, invasion and metastasis via modulation of various signaling pathways. Thus, chemokines and their receptors directly or indirectly shape the tumor cell microenvironment, and regulate the biological behavior of the tumor. In addition, the potential application of chemokines in chemotaxis of exosomes as drug vehicles is discussed. Exosomes containing chemokines or expressing receptors for chemokines may improve chemotaxis to HCC and may thus be exploited for targeted drug delivery.

Contents

1. Introduction
2. HCC-associated chemokines
3. Chemokines, exosomes and HCC
4. Conclusions and future prospects

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most common type of cancer worldwide and the third leading cause of cancer-associated death (1). Most patients cannot undergo radical surgery due to the presence of intrahepatic or distant organ metastases, and at present, the primary treatment methods for HCC include surgery, local ablation therapy and radiation intervention (2). These methods allow for effective treatment and management of patients with HCC during the early stages, with 5-year survival rates as high as 70% (3). Despite the continuous development of traditional treatment methods, the issue of recurrence and metastasis of HCC, causing adverse effects to the survival and prognosis of patients, remains a notable challenge. HCC is a heterogeneous and chameleonic disease, with involvement of the tumor microenvironment. HCC cells detach from the primary site, migrate and invade the extracellular matrix, transfer to the target organs and form metastatic lesions (4). Over 100 years ago, Paget (5) proposed the ‘seed and soil theory’ to explain the directional migration of cancer cells and invasion to specific organs. During tumor initiation, liver progenitor cells and hepatocytes are hypothesized to undergo genetic and epigenetic changes, which, together with disorders of the microenvironment, eventually give rise to a distinct subpopulation of cancer stem cells (CSCs) that have stem-like properties (6). Liver CSCs are considered to be responsible for HCC tumorigenesis, progression, metastasis and recurrence (7). Although significant progress has been made in the exploration of the mechanisms underlying the detachment of HCC cells, and therefore in migration and invasion, preventing HCC metastasis remains a poignant challenge for clinicians.

It has been found that chemokine networks may serve pivotal roles in inducing organ-specific metastasis (8). Chemokines are a class of small molecular proteins with similar structures, functions and chemotactic properties, and their molecular weights are ~10 kDa, and chemokines represent the largest member of the cytokine family (9). At present, >50 chemokines have been identified, which can be divided into four families: CXC, CX3C, CC and XC, based on the different positions of the conserved N-terminal cysteine residues (9). Chemokines bind to a variety of different receptors, which belong to the G-protein-binding receptor family, and there are ~23 types of chemokine receptors that have been discovered (10). The receptors are composed of seven
transmembrane domains connected by extracellular and intracellular loops and transfer signals by heterotrimeric Gi proteins (10). Chemokines and their receptors were initially thought to allow for an interaction between immune cells and the inflammatory sites (11). After binding to the receptors, chemokines primarily serve a role in migration of leukocytes, such as monocytes, eosinophils and dendritic cells (DCs) (11). Additionally, chemokines can directly act on non-immune cells, such as tumor cells and vascular endothelial cells, to regulate the proliferation, invasion and metastasis of tumor cells to promote the progression of cancer in the tumor microenvironment (9). In addition, with the action of specific chemokines, chemotaxis of different immune cell subgroups to the tumor microenvironment is observed, which allows further regulation of the tumor immune response (12).

In addition to typical chemokine receptors, chemokines can bind to the atypical chemokine receptor (ACKR) subfamily, which is a key regulator of the chemokine network, and is primarily expressed by stromal cells and endothelial cells (13). At present, ACKRs have not been shown to transmit signals, but instead function to degrade chemokines, thus controlling the extent of signal transduction (12). ACKR1 binds to >20 different CC and CXC chemokines (13). ACKR2 can bind to and degrade all CC family chemokines, and ACKR3 is the scavenging receptor of CXC motif chemokine ligand 12 (CXCL12) and CXCL11, which serves a key role in tumor development (14). In addition, ACKR4 primarily scavenges CC motif chemokine ligand 19 (CCL19), CCL21 and CCL25 (15,16). Therefore, chemokines and their receptors can directly or indirectly shape the tumor cell microenvironment, and then affect the proliferation, invasion and metastasis of tumor cells. The association between the chemokine regulatory network and the tumor is complex and tissue-dependent. Some chemokines serve a role in promoting cancer, whereas others have a cancer-suppressing effect; for example, CCL2, CXCL10 and CX3C motif chemokine ligand 1 (CX3CL1)/CX3C motif chemokine receptor 1 (CX3CR1) can serve as favorable or unfavorable prognostic factors depending on the specific type of cancer (17). With the in-depth study of chemokines, increasing attention has been paid to the biological role and mechanism of chemokines in the occurrence and development of HCC, particularly in the process of metastasis (12,17). In addition, chemokines on the exosomal surface may affect the chemotaxis of exosomes in the tumor microenvironment. The present review provides a summary of the relevant literature surrounding this topic, and discusses the association between HCC and chemokines.

2. HCC-associated chemokines

The morbidity (>20 cases/100,000 population in East Asia) and mortality (95%) rates of HCC remain high, and there are ~782,000 new cases and 600,000 deaths worldwide per year (18). And the liver, one of the most common metastatic organs of tumor cells, contains multiple cellular components, such as hepatic stellate cells, macrophages and sinusoidal endothelial cells, as well as acellular components, such as matrix metalloproteinases (MMPs) (4,19). Development of HCC may be associated with inflammation. Chronic liver inflammation causes continuous damage and regeneration of hepatocytes, which promotes the occurrence and development of HCC (19). Additionally, tumor-associated chronic inflammation involved the accumulation of immune cells to the tumor (20,21), and chemokines serve a key role in the recruitment and activation of immune cells, and participate in tumor progression, invasion and metastasis (22,23). HCC cells express a large number of chemokines and their receptors. Han et al (24) injected human hepatocellular carcinoma CBRH-7919 cells subcutaneously into nude mice, then compared the expression levels of genes involved in tumor progression between liver cancer and paracancerous tissues using chemokine microarray analysis. The results revealed that 50 chemokine-associated genes were upregulated and another 3 genes were downregulated in HCC, and western blotting confirmed the changes of CXCL1, CXCL2, CXC3L and CXC motif chemokine receptor 1 (CXCR1) expression in a CBRH-7919 mouse model (24). Additionally, silencing of the CXCL1 gene could inhibit the growth of CBRH-7919 tumors and significantly decrease the protein expression levels of CXCL2, CXCL3 and IL-1β (24). Dagouassat et al (25) demonstrated that CCL2 derived from liver stromal cells mediated the migration and invasion of HCC cells. Zhang et al (26) found that liver stromal cells activated by tumors increased chemokine secretion, including CCL1-6, CCL9, CCL12, CCL25, CXCL2, CXCL10 and CXCL12, and that chemotaxis was associated with various signaling pathways, including activation of the JAK-STAT signaling pathway and T-cell receptor signaling pathway. The aforementioned studies demonstrate that chemokines and their receptors, the expression of which is frequently observed in HCC, may serve as novel therapeutic targets. Table I shows the chemokines and their receptors associated with HCC.

Unlike CXCL12 and CXCL1, CXCL16 expression in the liver decreases when a tumor metastasizes to the liver (27). Typically, CXCL16 in the liver leads to the migration of M1 macrophages to the liver, which results in apoptosis of cancer cells by secreting TNF-α (28). In addition, the interaction between CXCR6 and CXCL16 leads to an increase in IL-4 secretion, which activates natural killer (NK) T cells to inhibit the proliferation of malignant cells (27). A study on gliomas revealed that CXCL16 and CX3CL1 downregulate the expression levels of vascular endothelial growth factor C (29), suggesting that they may inhibit tumor growth by decreasing angiogenesis. However, Takiguchi et al (30) found that soluble CXCL16 produced by mesenchymal stem cells (MSCs) via Wnt5a-Ror2 increased proliferation of human gastric cancer MKN45 cells expressing CXCR6. In vivo and in vitro experiments have demonstrated that by sequestrating CCL19 and CCL21, ACKR4 (also known as CCR1L) inhibits β-catenin from entering the nucleus, blocking the Akt-GSK3β signaling pathway (31). Subsequently, the expression levels of cancer-promoting factors cyclin D1 and c-Myc are decreased, achieving the effect of inhibiting HCC (31). Shi et al (32) revealed that the increase of CCR7+ mononuclear cells was significantly associated with worse survival and increased recurrence, and confirmed that ACKR4 had the potential to hinder CCR7+ cell chemotaxis to HCC tissues by inhibiting CCL19 and CCL21. The aforementioned studies suggest that chemokines have different effects in the tumor microenvironment, including HCC. However, the specific roles of...
Table I. Chemokine families.

A. CXC chemokine family

| Chemokine receptors | Chemokines | Functions | Signaling pathways | Role in HCC | (Refs.) |
|---------------------|------------|-----------|--------------------|--------------|--------|
| CXCR1               | CXCL6, CXCL7, CXCL8 | Chemotactic neutrophils are involved in innate immunity and acute inflammation | PI3K/Akt | Up regulation of CXCL6 transcription in HCC cells promotes HCC progression and metastasis | (108) |
|                     |            |           |                    | HCC plays an important role in invasion and metastasis | (136) |
| CXCR2               | CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 | Chemotactic neutrophils guide their migration to inflammatory sites | ERK1/2, PI3K/Akt | CXCR2-CXCL1 axis can regulate neutrophil infiltration into HCC tumor tissue | (137) |
|                     |            |           |                    | CXCL5 negatively regulates cell cycle in HCC cells; CXCL2 may play a key role in HCC metastasis | (89,138) |
|                     |            |           |                    | Overexpression of CXCL3 was significantly associated with tumor capsule formation and vascular invasion | (139) |
| CXCR3               | CXCL9, CXCL10, CXCL11 | It can promote the migration of T cells, promote the interaction between T cells and antigen presenting cells, and promote the production of effector cells and memory cells | Akt/mTOR/STAT3, MAPK | CXCR2-CXCL5 axis promotes EMT of HCC cells; CXCL5 can promote the invasion and proliferation of hepatoma cells by mediating the infiltration of neutrophils | (82,140) |
|                     |            |           |                    | HCC serves an important role in invasion and metastasis | (83) |
| CXCR4               | CXCL12     | It participates in the migration of stem cells, stimulates the proliferation of B cells and bone marrow cells, and it is also involved in the process of HIV invading normal human cells. | PI3K/Akt | CXCL12 and its receptor CXCR4 promote EMT; Cancer cells decrease apoptosis and achieve self-renewal | (93) |
| CXCR5               | CXCL13     | Involved in B-cell homing in lymphoid organs | Wnt/β-catenin | CXCL13 serves an important role in the development of liver cancer and it may have clinical value in the diagnosis and prognosis of liver cancer | (87,145) |
### Table I. Continued.

| Chemokine receptors | Chemokines | Functions | Signaling pathways | Role in HCC | (Refs.) |
|---------------------|------------|-----------|--------------------|-------------|---------|
| CXCR6               | CXCL16     | Promoting T-cell migration | Akt/mTOR | CXCL16 promotes HCC invasiveness and tumor inflammatory environment | (105,146) |
| CXCR7               | CXCL11, CXCL12 | Regulating the development and differentiation of B cells | MAPK AKT | Overexpression of CXCR7 promotes the growth and invasion of HCC; It plays an important role in promoting angiogenesis in liver cancer | (101,102) |

**B, CC chemokine family**

| Chemokine receptors | Chemokine | Functions | Signaling pathways | Role in HCC | (Refs.) |
|---------------------|-----------|-----------|--------------------|-------------|---------|
| CCR1                | CCL3, CCL5, CCL7-8, CCL13, CCL14, CCL15, CCL16, CCL23 | Chemotactic T cells and monocytes are involved in innate and adaptive immune response and inflammatory response | PI3K/Akt | CCL3-CCR1 axis serves an important role in the invasion and metastasis of HCC by changing the intracellular Ca concentration | (147) |
|                    |           |           | Inhibition of Wnt/β-catenin | CCL14 is a prognostic biomarker associated with immune invasion in HCC | (75,77) |
|                    |           |           | STAT3/Akt | It serves a key role in the metastasis of HCC | (136,150) |
|                    |           |           | - | Low CCL23 expression is not conducive to the formation of anti-tumor immune defense in patients with liver cancer, which significantly shortens the survival time of patients with liver cancer | (151) |
| CCR2                | CCL2, CCL7, CCL8, CCL13 | Mediating the expression of inflammatory T-cell cytokines induces macrophages and monocytes to recruit to inflammatory sites | Hedgehog | Regulating tumor growth, metastasis and host immune response to induce HCC cell invasion and EMT | (152) |
| CCR3                | CCL5, CCL7, CCL11, CCL15-16, CCL24, CCL26 | It serves an important role in the regulation of eosinophil migration | RhoB-VEGFA | It may promote the proliferation, migration and invasion of HCC, promote lung metastasis and promote the formation of human umbilical vein endothelial cells | (153) |
| CCR4                | CCL17, CCL22 | Chemotactic T cells and monocytes migrate to the skin and participate in allergic inflammation | Wnt/β-catenin ERK/Akt/MMP2 | CCL17 promotes the occurrence of HCC; CCL22 contributes to Treg recruitment and immunosuppression; CCR4 promotes HCC malignant tumor and HCC cell metastasis | (154,155,156) |
Table I. Continued.

| Chemokine receptors | Chemokines | Functions                                                                 | Signaling pathways | Role in HCC                                                                 | (Refs.) |
|---------------------|------------|---------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------|---------|
| CCR5                | CCL3, CCL4, CCL5, CCL8 | Mediating the chemotaxis of macrophages and T cells. Promoting HIV penetration into normal human cells. | -                  | Promoting tumor occurrence and development; It leads to the growth, proliferation and migration of hepatoma cells; Regulating EMT and promoting HCC metastasis | (157, 68) |
| CCR6                | CCL20      | Dendritic cells, memory T cells and Th17 cells were chemotactic to inflammatory sites | STAT3              | It is involved in regulating the migration and invasion of HCC; Tregs mediate the chemotaxis of Tregs to the tumor microenvironment and promote liver cancer | (62,64) |
| CCR7                | CCL19, CCL21 | It promotes the recycling of immature T cells, and T cells homing to the secondary lymphoid tissue | -                  | CCL19 may serve an inhibitory role in the invasive regulation of human HCC CCR7 promotes the development of HCC and is associated with poor survival | (158, 31,159) |
| CCR8                | CCL1       | It is involved in T-cell migration and Th2 response and regulates monocyte chemotaxis and thymocyte apoptosis | PKM2-ARRDC1        | CCL1/CCR8 axis promotes PKM2 excretion in HCC cells                          | (160)   |
| CCR9                | CCL25      | Regulation of lymphocyte epithelial interaction in small intestinal mucosa; Involved in multiple stages of adult T lymphocyte production | -                  | It is concluded that the regulation of multiple EMT markers serves an important role in the migration and invasion of HCC cells, enhances the colony forming ability of hepatoma cells and their tumorigenicity, and is an independent prognostic factor for the overall survival of patients with HCC | (161)   |
| CCR10               | CCL27, CCL28 | Key regulators of skin immune homeostasis; Regulating intestinal IgA response and memory maintenance | PI3K/Akt           | Inflammation drives hepatocarcinogenesis                                      | (60)    |

C, CX3C chemokine family

| Chemokine receptors | Chemokine | Functions                                                                 | Signaling pathways | Role in HCC                                                                 | (Refs.) |
|---------------------|-----------|---------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------|---------|
| CX3CR1              | CX3CL1    | Chemotactic lymphocytes and macrophages; It also has a chemotactic effect on microglia | STAT3, Src/PTK2   | CX3CL1 stimulates chemotaxis and cytotoxicity of CX3CR1 natural killer cells; CX3CL1 induces invasion and migration of HCC cells into the spine | (34,39) |
chemokines in different cellular microenvironments and the underlying mechanisms require further study.

**CX3C.** As the only member of the CX3C chemokine subfamily, CX3CL1 is a transmembrane glycoprotein that exists in two forms: Membrane-bound and secretory. In addition, the mucin-like domain of CX3CL1 contains a cleavage site that allows metalloproteinases (such as ADAM10) to cleave and release proteins in a soluble form (33). CXCR3 is the only receptor of CX3CL1, and CX3CL1/CX3CR1 regulates the chemotaxis of inflammatory cells, as well as the proliferation, migration, and invasion of cancer cells (34,35). It has been reported that CX3CL1 is closely associated with the metastasis of prostate (36) and breast cancer (37). Additionally, these studies confirmed that inhibition of CX3CL1 was an effective strategy to prevent spinal metastasis of breast and prostate cancer (36,37). Sun et al (34) revealed that CX3CL1/CX3CR1 expression in HCC spinal metastases was upregulated. Bone marrow endothelial cells promote the migration and invasion of Hep3B and MHCC97H cells to the spine by secreting soluble CX3CL1 and this is inhibited following neutralization of CX3CL1 (34). In CX3CR1 gene-deficient mice, Zheng et al (38) found that the metastasis of colon cancer cells to the liver was significantly suppressed, and the upregulation of CX3CR1 gene expression in tumor-associated cells was associated with worse prognosis. Additionally, it was confirmed that CX3CR1 deficiency inhibited macrophage aggregation and promoted macrophage apoptosis in metastatic tumors, thus serving an antitumor effect (38). Considering the dual functions of CX3CL1 as a chemottractant for leukocytes and adhesion molecules for tumor cells, CX3CL1 may have dual effects, promoting tumor progression or antitumor effects (35). Chen et al (39) found that the increase of CX3CL1 expression levels were associated with liver metastasis and poor prognosis after hepatectomy. Additionally, it was shown that miR-561-5p downregulated CX3CL1 mRNA expression, leading to a decrease in chemotaxis, functional regulation and infiltration of CX3CR1+ NK cells, thus promoting HCC growth and lung metastasis (39). Miao et al (40) demonstrated that members of the CX3CR1/Syk/PI3K signaling pathway were essential for CX3CL1-induced platelet migration, which induced apoptosis of HCC cells in vitro, thus inhibiting HCC growth. These studies suggest that CX3CL1/CX3CR1 are potential therapeutic targets against HCC growth and metastasis. Interference with CX3CL1/CX3CR1 may have future clinical implications for HCC prevention and treatment.

**XC.** Among the four types of chemokines, there are two highly homologous XC chemokines: XC motif chemokine ligand 1 (XCL1) and XCL2, whose genes (SCYC1 and SCYC2, respectively) are located on chromosome 1. There are only two amino acid differences between them, and XCL1 is the variant with the predominant effect (41). Unlike CXC, CC and CX3C chemokines with two disulfide bonds and four cysteine residues at the N-terminal, XCL1 has only one disulfide bond and two cysteine residues (42). XC motif chemokine receptor 1 (XCR1) is the receptor of XCL1, and human XCR1 is primarily expressed in BDCA3+CD141+ DCs, which serve an important role in antigen presentation and enhancing cytotoxic T-cell response (43). Similar to other family members, XCR1 serves an important role in human tumors. Several studies have revealed that XCR1 expression is upregulated in ovarian, oral and breast cancer, where it promotes cancer cell proliferation, adhesion, migration and invasion (44-46). For example, Kim et al (46) found that XCR1 was expressed in both primary and metastatic human epithelial ovarian cancer specimens and cell lines, but not in normal ovaries or ovarian surface epithelial cells, highlighting the association between XCR1 and cell carcinogenesis and migration. Wang et al (47) revealed that XCL1/XCR1 significantly promoted the proliferation and migration of lung cancer cells, whereas the role of XCL1 in cell proliferation and migration was abrogated following XCR1-knockdown using small interfering RNA. However, not all studies support this conclusion. Another study assessed XCR1 expression in an HCC cell line and on the proliferation, metastasis and invasive ability of HCC (48). In vitro, it was found that XCR1 silencing promoted the migration and invasion of HCC, whereas the overexpression of XCR1 had the opposite effect, and the mechanism may be associated with the inhibition of epithelial-mesenchymal transition (EMT) (48). Additionally, overexpression of XCR1 in HCCLM3 cells decreased tumor growth, partially due to the inhibition of the MAPK and PI3K/Akt signaling pathways (48). The aforementioned studies indicate that XCR1 may have different roles in different tumors and thus warrants further study.

It has been demonstrated that XCR1+ DCs can promote the antitumor immune response and lead to tumor cell death (49). Using a fusion protein composed of a tumor antigen and XCL1

| Chemokine receptors | Chemokine | Functions | Signaling pathways | Role in HCC | (Refs.) |
|---------------------|-----------|-----------|--------------------|-------------|--------|
| XCR1                | XCL1, XCL2| Establishment of regulatory thymic tolerance and production of Tregs | MAPK and PI3K/Akt | High XCR1 expression is positively associated with EMT, which is closely associated with tumor migration and invasion | (48) |

HCC, hepatocellular carcinoma; EMT, epithelial-mesenchymal transition; Tregs, regulatory T cells; Th, T helper; HIV, human immunodeficiency virus.

Table I. Continued.
to target and activate XCR1⁺CD141⁺ DCs, CD8⁺ T-cell activation was induced to elicit an antitumor effect (50). In humans, high quantities of CD141⁺ DCs are associated with improved prognosis (51). In another study, fusion proteins composed of XCL1 fused to an ovalbumin (OVA) synthetic long peptide and IgG1 Fc fragment was established; the specific binding and uptake of XCL1 fusion protein by XCR1⁺ DCs enhanced the response of CD8⁺ T cells and delayed the progression of B16-OVA melanoma (52). Chen et al (53) constructed a fusion molecule of XCL1 as a liver cancer vaccine by creating a fusion of XCL1 with glypican-3 (GPC3). The cells expressing XCL1-GPC3 were chemotactic and attracted mouse XCR1⁺CD8⁺ αβ DCs and human XCR1⁺CD141⁺ DCs, to promote the production of IL12 in vitro (53). XCL1-GPC3-targeted DCs can enhance the proliferation of antigen-specific CD8⁺ T cells and induce the regeneration of GPC3-specific CD8⁺ T cells, thus decreasing the development of HCC via GPC3 expression in mouse and human systems (53). At present, several clinical trials have been performed assessing the biology and therapeutic potential of DCs, but thus far, their clinical applications have remained unsatisfactory. It has been hypothesized that XCR1⁺ cross-presentation subsets may be used as a potential target of next generation DC-based therapy, as XCR1⁺ DCs have the unique ability to stimulate CD8⁺ T cells and regulate antitumor effects (54,55). Taking the most effective intervention measures to enhance the migration, activation, maturity and function of XCR1⁺ DCs is essential to fully exert their anticancer potential. Targeting XCR1⁺ DCs using a fusion protein of various antigens, including neoantigens and human XCL1/2, may exhibit potential as promising antitumor therapy.

CC. The CC chemokine subfamily consists of >20 members, and the N-terminal of the members contain two adjacent cysteine residues (9). CC chemokines serve indispensable roles in HCC. It has been demonstrated that CCL2 promotes HCC invasion and the effect of EMT, accompanied by the activation of the Hedgehog signaling pathway (56). Additionally, CCL2 can stimulate angiogenesis and further promote the progression of liver cancer (56). The combination of CCL2 with CCR4⁺ regulatory T cells (Tregs) and CCR2⁺Ly-6C⁺ myeloid-derived suppressor cells (MDSCs) affects the glioma microenvironment and causes immunosuppression, thus promoting tumor development, which indicates that CCL2/CCR2 and CCL2/CCR4 serve a crucial role in inducing the migration of mononuclear-MDSCs to precancerous lesions (57,58). Qi et al (59) confirmed that CCL7 and its receptor CCR3 were key mediators of invasion and metastasis of liver and colon tumor cells. CCL7 modulates signal transmission by binding to CCR1, CCR2 and CCR3, the expression levels of which are upregulated in liver metastases, with CCR3 exhibiting higher expression levels than CCR1 or CCR2 (59). Furthermore, it was revealed that CCL7 regulated the transport of MMP-9 to invasive cells through its receptor CCR3, thus promoting the formation of functional invasive cells, degrading collagen and invading extracellular matrix, a key condition for HCC migration (59). Via targeted gene expression microarray screening alterations in G-protein coupled receptor family gene expression, Wu et al (60) found that CCR10 was significantly upregulated in inflammation-driven HCC tumors and paracancerous tissue hepatocytes. Additionally, CCR10, secreted by hepatocytes, activates the PI3K/Akt signaling pathway via Akt phosphorylation, and inhibits apoptosis and promotes compensatory proliferation to drive the occurrence of HCC (60). CCR6 is another member of the CC chemokine receptor family, and its ligand CCL20 is also known as macrophage regulatory protein 3α (20). It has been reported that CCR6 is highly expressed in a variety of cancer cells and participates in different tumor-associated behaviors (61). Several studies have demonstrated that CCL20/CCR6 promotes the proliferation, adhesion and chemotactic migration of HCC cells (62,63). CCL20 mediates the chemotaxis of Tregs to the tumor microenvironment and this process is achieved via the activation of STAT3 (64). Furthermore, the expression of epidermal growth factor receptor/Ras-induced CCL20 in the tumor microenvironment stimulates tumor microangiogenesis, leading to rapid tumor growth and progression (64). Blocking the activity of CCR6 in the tumor microenvironment may inhibit tumor neovascularization and enhance traditional antitumor therapy (61). CCR6, the specific receptor of CCL20, may be a promising anticancer target. Other CC members, such as CCL28, promote the infiltration of Tregs into the tumor environment, induce angiogenesis and facilitate tumor cell escape from immune surveillance (65). Gao et al (66) reported that CCL15 secreted by HCC cells can promote chemotaxis to cancer foci by binding to CCR1 on the membrane of MSCs. Although unmodified MSCs have no significant effect on the progression of HCC tumors, they are considered to be a promising gene delivery vector in tumor therapy (66). In addition, due to the similar phenotypes of CCR7⁺ monocytes and Tregs, they can both promote tumor progression by producing TGF-β1 (32). The aforementioned studies highlight novel therapeutic targets for the treatment of HCC.

CCL5 can bind to CCR1 and CCR3, but the activity of CCL5 is exerted by binding to CCR5 (63,67). CCL5/CCR5 expression in HCC tissues is significantly higher compared with in non-neoplastic liver tissues, and CCL5 binding to CCR5 activates the PI3K/Akt/mTOR signaling pathway, which is associated with the occurrence and development of HCC, and the CCR5 antagonist, maraviroc, reverses this effect (67). Additionally, CCL5/CCR5 regulates EMT, promoting HCC metastasis (68). Furthermore, macrophages exposed to hepatitis C virus exhibit increased secretion of CCL5, which further activates hepatic stellate cells to induce hepatitis and liver fibrosis (69), highlighting the biological and clinical significance of CCL5/CCR5 in the development of HCC. As CCR5 exists in immune cells and cancer cells, it can exert dual effects, both antitumor and tumor-promoting effects (70). Thus, the function of CCL5/CCR5 remains controversial. However, in general, CCL5/CCR5 serves a major role in promoting tumors (68). These findings suggest that CCL5/CCR5 may be a potential target for the treatment of HCC.

The CC subfamily is also associated with tumor drug resistance. In lung cancer, CCL2 is associated with docetaxel resistance via activation of the PI3K/Akt signaling pathway where it inhibits caspase3-dependent apoptosis (71). In addition, stroma-derived CCL2 and CCL5 induce tumor cells to release IL-6 by activating the PYK2 signaling pathway (located upstream of the JAK1/STAT3 signaling pathway), thereby resulting in carboplatin resistance (72). Similarly, the regulation of CCL20 expression via ATP-binding cassette
subfamily B member 1 membrane transporter is associated with doxorubicin resistance (73). Vaquero et al (74) examined 109 genes that may be associated with chemotherapeutic drug resistance in HCC and found that CCL14 and CCL15 mRNA expression was upregulated following activation of nuclear receptor FXR; this upregulation was involved in drug resistance and the mechanism of chemoresistance (MOC) may be associated with changes in the balance of apoptosis-promoting (MOC-5a) and survival-promoting (MOC-5b) genes. By detecting the expression levels of CC chemokines associated with drug resistance and by performing targeted blocking, the efficacy of chemotherapy drugs may be improved.

Not all CC subfamily chemokines promote tumor progression. Gu et al (75) found that CCL14 expression in certain types of human cancer was significantly lower compared with in normal tissues, such as in HCC. Low CCL14 expression is associated with improved overall survival, disease-specific survival, progression-free survival and recurrence-free survival in patients with HCC, particularly in the early stages of disease, and CCL14 is strongly associated with tumor infiltrating B cells, CD4+ and CD8+ T cells, DCs, neutrophils and macrophages (75). CCL14 binds to chemokine receptors such as CCR1, CCR3, and CCR5, and regulates the activation and migration of different leukocytes by mobilizing Ca2+ influx (76). CCL14 expression in HCC is negatively associated with the expression levels of several immune cell markers, including programmed death receptor-1, T-cell immunoglobulin mucin-3 and cytotoxic T-lymphyocyte associate protein-4, suggesting the role of CCL14 in tumor immune regulation (75). Zhu et al (77) used tissue microarrays to analyze CCL14 expression in tumor and paracancerous tissues, revealing that CCL14 expression was downregulated in liver cancer tissues compared with in the surrounding tissues. Overexpression of CCL14 inhibits the proliferation of HCC and promotes apoptosis (77). Additionally, the results of animal experiments confirmed that CCL14 could inhibit the growth of tumors in nude mice and notably, experimental data suggest that CCL14 may exert these effects by inhibiting the activation of the Wnt/β-catenin signaling pathway (77). Zhang et al (78) confirmed that CCL14 was stable and effective in predicting the survival rate and recurrence time of patients with HCC via RNA sequencing analysis of 330 specimens. These findings suggest that CCL14 may be used as a biomarker to predict the prognosis of patients with HCC and may be a potential target for the treatment of HCC.

In summary, CC subfamily chemokines are increasingly considered to be involved in a variety of tumor biological processes, and are closely associated with the development, metastasis and regulation of the tumor microenvironment of HCC. However, further studies and novel techniques/therapeutics are required to improve the diagnosis and treatment of HCC effectively via regulation of CC subfamily chemokines.

CXC. In normal liver tissues, CXC chemokines are widely involved in the repair of hepatocyte injury by affecting hepatocyte proliferation and regeneration (79), and they serve an important role in the occurrence and development of HCC and the tumor microenvironment. Although the ligands and receptors have high sequence homology (~80%), the ligand selectivity of receptors varies, and CXC chemokines are divided into two groups according to the presence or absence of Glu-Leu-Arg (ELR motif) at the amino terminal, which exerts a vital effect on tumorigenesis and development, particularly in tumor angiogenesis (80). Members containing the ELR motif (including CXCL1, 2, 3, 5, 6, 7 and 8) bind to CXCR2 and exert angiogenic effects, whereas most CXC chemokines without the ELR motif bind to CXCR3 and lead to vascular inhibition (80). For example, the CXCL5/CXCR2 axis is involved in EMT in HCC by activating the PI3K/Akt/GSK-3β/Snail signaling pathway and significantly enhances the proliferative, migratory and invasive abilities of HCC cells (81,82). CXCL8, also known as IL-8, is usually secreted by tumor cells and inflammatory cells (12). In HCC, the levels of CXCL8 are significantly increased compared with in normal liver tissue, leading to progression and metastasis by activating the AKT/mTOR/STAT3 signaling pathway (83).

Studies have shown that neutrophils expressing CXCR2 chemotactically enter the liver by binding to CXCL1 (84), releasing MMP8 and MMP9 to induce angiogenesis (85). Additionally, CXCL8 increases immune infiltration of Tregs into the tumor microenvironment (22). Therefore, evaluating the expression levels of chemokines in the liver may be a prognostic factor for follow-ups in patients with HCC. CXCL10 expression is positively associated with increased serum α-fetoprotein levels, tumor size, tumor number and TNM stage (86). Kaplan-Meier survival curve analyses revealed that the overall survival rate and disease-free survival rate of patients with high CXCL10 expression was low; additionally, univariate/multivariate analyses demonstrated that CXCL10 was an independent prognostic factor for patients with HCC (86). By measuring the levels of CXCL13 in patients with HCC, Li et al (87) found that CXCL13 levels in patients with tumors >5 cm were significantly higher compared with those in patients with tumors <5 cm in size, and the levels of CXCL13 were positively associated with Child-Pugh score and negatively correlated with albumin and cholinesterase levels. It has been suggested that CXCL13 may be used as an index to evaluate liver function (87). Song et al (88) reported that CXCL2 expression was upregulated in the blood of patients with HCC and promoted the proliferation and metastasis of HepG2 and PG5 cells. Conversely, Ding et al (89) overexpressed CXCL2 in MHCC97H and HCCLM3 cell lines using lentiviral transfection, and revealed that the exogenous expression of CXCL2 inhibited cell proliferation by promoting apoptosis and cell cycle arrest at the G, phase. Additionally, Subat et al (90) found that CXCL2 levels were significantly downregulated in tumor tissues compared with in normal liver tissues, but high CXCL2 expression was positively associated with the number of HCC tumors. This may be due to different molecular mechanisms of occurrence and development in different tumor cell lines.

The role of CXCL12 is very important in the development of HCC. In the past, it was considered that CXCR4 was the only receptor of CXCL12. CXCL12/CXCR4 binds specifically and is commonly involved in various pathophysiological processes, such as anti-apoptotic and angiogenesis processes (29). Additionally, CXCL12/CXCR4 serves a key role in cell migration to multiple organs, including the liver, bone marrow and lungs (91). Additionally, CXCL12/CXCR4 can promote EMT (92), decrease apoptosis and allow for self-renewal of cancer cells by activating the anti-apoptotic
PI3K/Akt signaling pathway (93), increase the expression levels of hypoxia-inducible factor and activate MMPs, thereby jointly promoting angiogenesis and cancer metastasis (94,95). Wang et al (96) found that the hepatitis B virus (HBV) X protein (HBx) enhanced MDM2 expression by directly binding to MDM2 and inhibiting its ubiquitin degradation, resulting in enhanced transcriptional activity and CXCL12 and CXCR4 expression, which in turn activated the Wnt/β-catenin signaling pathway and enhanced the activity of OV6+ CSCs. In addition, the aforementioned study indicated that the expression levels of any two markers of the HBx/MDM2/CXCR4/OV6 axis in HCC biopsies could be used to predict the prognosis of patients with HBV-associated HCC (96). Another study demonstrated that the occurrence rate of CXCR4 in the blood vessels of liver cancer was ~50%, and that high CXCR4 expression indicated a poor prognosis (97). These results suggest that CXCR4 may be a prognostic factor and a potential therapeutic target for HCC (Fig. 1). Knocking down CXCR4 gene expression using small interfering RNA results in decreased invasiveness of uveal melanoma cells exposed to soluble factors produced by the human liver (98). The U.S. Food and Drug Administration has approved the CXCR4 antagonist plerixafor (Mozobil, AMD3100) for peripheral blood stem cell mobilization following an autologous transplantation (99). In addition, Collins et al (100) hypothesized that CXCL14 may be a positive allosteric modulator of CXCR4, enhancing the potency of CXCR4. CXCR7 is another high affinity receptor of CXCL12, which activates the Akt signaling pathway to induce angiogenesis in HCC (101) and stimulates MAPK signal transduction to promote HCC growth and invasion (102). These studies suggest that CXCL12 and its receptors serve a role that cannot be ignored in the development of HCC.

CXCR3 is expressed in almost all cells, is upregulated in several types of primary and metastatic tumors (such as renal cancer, colon cancer and pulmonary metastasis tumor), and is considered to be essential for migration of cancer cells (12,103). Three variants of CXCR3 (CXCR3-A, CXCR3-B and CXCR3-alt) have been identified, and two of these, CXCR3-A and CXCR3-B, induce opposing physiological functions (103). Overall, CXCR3-A promotes cell proliferation, survival, chemotaxis, invasion and mediates tumor metastasis, whereas CXCR3-B inhibits tumor growth and promotes apoptosis and angiogenesis (104). Therefore, abnormal expression levels of CXCR3-A and CXCR3-B can affect the progression of a tumor. Compared with CXCR3-A, CXCR3-alt possesses a substantially different C-terminal protein sequence, which differs from all known chemokine receptors (104). However, there are few studies on CXCR3-alt (104). At the cellular level, it has been shown that knocking down CXCR3 significantly inhibits the proliferation, adhesion, migration and invasion of HCC cells (86), Gao et al (105) reported that high CXCR6 expression promotes the invasion of HCC and the generation of an inflammatory environment, and is associated with a poor prognosis in patients with HCC. These results support the view that inhibition of the CXCL16/CXCR6 pathway may improve the prognosis of HCC treatment. CXCR7 is highly expressed in tumor endothelial cells, enhancing HCC migration and invasion by affecting the phosphorylation of the

**Figure 1.** CXCL12/CXCR4 can induce angiogenesis, EMT and myeloid-derived suppressor cells to promote the progression of HCC. Additionally, CXCL12/CXCR4 expression enhances the activity of OV6+ liver cancer stem cells via the Wnt/β-catenin signaling pathway, thus enhancing invasion and migration of HCC. In addition, CXCL12/CXCR4 can directly promote HCC growth and metastasis. CXCL12, CXC motif chemokine ligand 12; CXCR4, CXC motif chemokine receptor 4; EMT, epithelial-mesenchymal transformation; HCC, hepatocellular carcinoma; OV6, oval cell marker.
3. Chemokines, exosomes and HCC

Exosomes are microvesicles secreted by cells with a diameter of 30-100 nm (109) which are widely present in several body fluids, such as serum, milk, semen and malignant effusions (110). As intercellular messengers, exosomes are involved in the occurrence, development and metastasis of tumors, participating in several biological processes, such as the inflammatory immune response, cell survival and apoptosis, angiogenesis, thrombosis, autophagy and intercellular signal communication (111-113). The multiple functions of exosomes have attracted wide attention in the past few decades. Exosomes mediate the transport of proteins, DNA and various forms of RNA, such as microRNAs (miRs), long non-coding RNAs and mRNAs, between cells, thus promoting the occurrence and development of HCC (114,115). Sun et al (116) demonstrated that miR-155 was enriched in the exosomes released by HCC cells, and the exosomes rich in miR-155 entered new liver tumor cells and promoted the proliferation of HCC cells. Compared with conventional liposomes, exosomes have low toxicity, low immunogenicity and good bioavailability (117). For example, previous studies reported that exosomes produced by HeLa cells, DCs and MSCs did not induce an inflammatory response (118,119). Therefore, the use of modified exosomes as a drug carrier to deliver drugs to the tumor to improve drug availability and decreased side effects has been proposed (120). As an example, paclitaxel was integrated into exosomes released by macrophages to treat multidrug-resistant cancers (121). Compared with free drugs, the cytotoxicity of exosome-mediated transport of drugs into drug-resistant cells increased by >50 times (121). However, there are still certain technical obstacles to overcome before these approaches can be implemented in clinical practice, such as challenges on the stability of this components, as well as a lack of targets (122).

It is generally hypothesized that exosomal membrane surface proteins bind to the receptors of the target cell, then transport the cargo into the cell (123). In order to better target cells, and improve the stability of exosomes in vivo, surface modifications are required. With the development of new technologies, studies have used efficient surface labeling technology to manufacture monoclonal antibody (mAb) exosomes (124,125). Flow cytometry and confocal laser scanning microscopy revealed that SSTR2 mAb-exosomes and SSTR-overexpressing neuroendocrine cancer cells exhibited strong bonding; additionally, in vitro and in vivo studies confirmed that SSTR2 mAb-exosomes effectively delivered romidepsin to tumor cells (122). Compared with the control group, the treatment group exhibited delayed tumor progression and exhibited low toxicity and minimal side effects (122). It has been confirmed that integrins expressed on exosomes serve an important role in promoting the uptake of tumor-derived exosomes by endothelial cells and MSCs (126,127). Hoshino et al (128) reported that different exosomes expressed different integrins, which determined the chemotaxis of exosomes to specific organs. After loading sorafenib into exosomes modified by glucose-related protein 78 small interfering RNA secreted by bone marrow-derived MSCs, Li et al (129) found that these exosomes enhanced drug loading in drug-resistant HCC, as well as preventing the development and metastasis of cancer cells, indicating that the modified exosomes have attractive chemotaxis properties. These studies suggest that modified exosomes exhibit broad potential for drug delivery in specific types of cancer.

Whether chemokines are expressed on the surface of exosomes, and whether they promote the chemotaxis of exosomes to HCC has been investigated. Viñas et al (130) observed that CXCL12 expression in kidneys was increased and that exosomes expressing CXCR4 were enriched in mice with renal ischemia/reperfusion injury. Further experiments revealed that hypoxia promoted CXCL12 expression in human umbilical vein endothelial cells (HUVECs) (130). Compared with normal cells, HUVECs exposed to hypoxia increased uptake of CXCR4-expressing exosomes, and was significantly inhibited by the CXCR4 inhibitorplerixafor (130). The aforementioned study revealed the effect of CXCL12/CXCR4 in the chemotaxis of exosomes to kidney endothelium. Additionally, Ciullo et al (131) found that in a mouse model of cardiac ischemia-reperfusion, compared with the exosomes that did not express CXCR4, the exosomes expressing CXCR4 migrated more effectively using chemotaxis to the CXCL12-expressing cardiomyocytes and exerted improved cardioprotective effects. Gao et al (132) found that the accumulation of exosomes produced by mature DCs in the spleen is regulated by CCR7 on the exosomal membrane surface. A decrease in CCR7 expression decreases the accumulation of exosomes in the spleen and decreases the inflammatory reaction (132). In HCC, CXCL12 expression is significantly increased compared with in normal liver tissues (107). Theoretically, the exosomes expressing CXCR4 may more effectively induce chemotaxis to HCC and thus serve a role in targeted drug delivery. Thus, it was hypothesized that the surface of modified HCC exosomes overexpressing chemokine receptors, such as CXCR4, and loaded with antitumor drugs, may enhance the chemotaxis of exosomes to HCC and achieve the goal of targeted therapy (Fig. 2). Although exosomes have received widespread attention, studies on this subject remain limited, and the complexity of exosomes in the treatment of liver cancer is not fully understood. In future studies, the association between exocrine chemotaxis and chemokines should be further determined to lay the foundation for the study of exosome-directed drug delivery to the liver.
4. Conclusions and future prospects

There is an urgent need to identify novel therapeutic strategies for the management of HCC due to the poor prognosis of patients. In recent years, immunotherapy and molecular targeted therapy have become increasingly popular. However, the unique immune response in the liver favors tolerance, which represents a substantial challenge for conventional immunotherapy in patients with HCC (133). Altering the tumor microenvironment and preventing immune tolerance are the goals of novel immune-based methods. HCC typically develops alongside or following various other liver diseases (such as hepatitis and cirrhosis), in which the constant inflammation process enhances the formation and growth of the tumor (134). In a review by Gnoni et al (4), it was suggested that the cells present in the microenvironment, such as macrophages, activated stellate cells and blood (platelets) cells, contribute to stimulate and enhance tumorigenesis, angiogenesis and metastases of HCC. Chemokines and their receptors not only affect the progression of HCC directly or indirectly, but also serve an important biological role in the migration of these cells, broadening the research field to include host and tumor interactions. For example, CCL15 recruits CCR1+CD14+ monocytes to the HCC invasive margin, and these monocytes in turn suppress the antitumor immune response, promote angiogenesis and accelerate HCC metastasis (135). Blockage of the CCL15-CCR1 axis decreases HCC growth and metastasis in vivo, representing a promising therapeutic approach (135). Based on the involvement of tumor-associated macrophages in cancer survival and proliferation, targeting the chemokines and their receptors may result in a valuable prognostic impact and may assist in the identification of novel immunity-based cancer treatments. It is hypothesized that patients with HCC may obtain more benefits when chemokines/receptors are regulated.

In addition, exosomes, which mediate the transport of various proteins, DNA and RNA molecules, may be used as drug carriers; exosomes expressing chemokines can more effectively induce chemotaxis to specific lesions (131-133). Thus, there is significant potential for exosomes modified by chemokines to deliver drugs directly, thus inhibiting the occurrence and development of HCC, and this highlights the future direction for further research.

Acknowledgements

Not applicable.

Funding

The present review was supported by the Hebei Provincial Government Clinical Medicine Talents Training and Basic Research Project (grant no. 361003).

Availability of data and materials

Not applicable.

Authors' contributions

DX and YZ wrote and reviewed the manuscript. DX, YL and JH designed the figures. DX, JH and JW edited the manuscript. DX, YZ and JW assessed all the raw data. YP and HT critically revised the manuscript. YL, YP and HT are responsible for the content and implementation of the research project.
for confirming the authenticity of the data. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Dong G, Zhang S, Shen S, Sun L, Wang X, Wang H, Wu J, Liu T, Wang C, Wang H, et al: SPATS2, negatively regulated by miR-145-5p, promotes hepatocellular carcinoma progression through regulating cell cycle. Cell Death Dis 11: 837, 2020.

2. Zhang FP, Huang YP, Luo WX, Deng WY, Liu CQ, Xu LB, et al: Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment. World J Gastroenterol 26: 134-153, 2020.

3. Zhang XF, Yang X, Jia HL, Zhu WW, Lu L, Shi W, Zhang H, Chen JH, Tao YF, Wang ZX, et al: Bel-2 expression is a poor predictor for hepatocellular carcinoma prognosis of andro-pause-age patients. Cancer Biol Med 13: 459-468, 2016.

4. Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V, et al: Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets 19: 1623-1635, 2015.

5. Paget S: The distribution of secondary growth in cancer. Lancet 1: 571-573, 1889.

6. Sainz B and Heeschen C: Standing out from the crowd: Cancer stem cells in hepatocellular carcinoma. Cancer Cell 23: 431-433, 2013.

7. Li J and Zhu Y: Recent advances in liver cancer stem cells: Non-coding RNAs, oncogenes and oncoproteins. Front Genet 8: 548335, 2020.

8. Kakinuma T and Hwang ST: Chemokines, chemokine receptors, Non-coding RNAs, oncogenes and oncoproteins. Front Cell Dev Biol 7: 224, 2018.

9. Rakoff-Nahoum S, Sher A and Medzhitov R: Inflammatory regulatory T cells: A functional perspective. Annu Rev Immunol 37: 571-604, 2019.

10. Sakai N, Yoshidome H, Shida T, Kimura F, Nakayama T, Yoshide O, et al: Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep 29: 975-982, 2013.

11. Shi JY, Tada N, Hashimoto I, Igarashi Y, Tsukada K, Shiba Hara N, Takasaki F, et al: Inflammatory regulatory T cells in the liver. Clin Exp Immunol 2015: 3942-4435, 2020.

12. Takiguchi G, Nishita M, Kurita K, Kakeji Y and Minami Y: Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 signaling. Cancer Cell 37: 290-297, 2015.

13. Shi JY, Lyon L, Wang ZC, Wang LY, Zhou J, Wang X, Shi GM, Ding ZB, Ke AW, Dai Z, et al: CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma. J Pathol 235: 456-558, 2015.

14. Shi JY, Duan M, Sun QM, Yang L, Wang ZC, Mynbaev OA, et al: Role of CX3CL1 in diseases. Arch Immunol Ther Exp (Warsz) 56: 359-370, 2018.

15. Purvanov V, Matti C, Samson GPB, Kindinger I and Legler DF: Fluorescently tagged CCL19 and CCL21 to monitor CCR7 and ACKR4 functions. Int J Mol Sci 19: 3587, 2018.

16. Matti C, D’Uonnolo G, Artinger M, Melgrati S, Salnikov A, Thelen S, Purvanov V, Strobel TD, Spannagel L, Thelen M and Legler DF: CCL20 is a novel ligand for the scavenging atypical chemokine receptor 4. J Leukoc Biol 107: 1137-1150, 2020.

17. Do HTT, Lee CH and Cho J: Chemokines and their receptors: Multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel) 12: 287, 2020.
38. Zheng J, Yang M, Shao J, Miao Y, Han J and Du J: Chemokine receptor CX3CR1 contributes to macrophage survival in tumor metastasis. Mol Cancer 12: 141, 2013.

39. Chen EB, Zhou ZJ, Xiao K, Zhu GQ, Yang Y, Zhou B, Zhou SL, Chen Q, Yin D, Wang Z, et al: The miR-561-5p/CXCL1 signaling axis regulates pulmonary metastasis in hepatocellular carcinoma involving CXCR1* natural killer cells infiltration. Theranostics 9: 4779-4794, 2019.

40. Miao S, Lu M, Liu Y, Shu D, Zhu Y, Song M, Ma Y, Ma R, Zhang B, Fang C and Ming ZY: Platelet uptake to hepatocellular carcinoma tissues in a CX3CL1-CXCR1 dependent manner and induce tumor cell apoptosis. Mol Oncol 14: 2546-2559, 2020.

41. Yoshida T, Imai T, Takagi S, Nishimura M, Ishikawa I, Yaoi T and Yoshiie O: Structure and expression of two highly related genes encoding SCM-1/human lymphotactin. FEBS Lett 395: 92-98, 2000.

42. Lei Y and Takahama Y: XCL1 and XCR1 in the immune system. Microbes Infect 14: 262-267, 2012.

43. Yamazaki C, Sugiyama M, Ohta T, Hemmi H, Hamada E, Yoshida T, Imai T, Takagi S, Nishimura M, Ishikawa I, Yaoi T and Yoshiie O: Structure and expression of two highly related genes encoding SCM-1/human lymphotactin. FEBS Lett 395: 92-98, 2000.

44. Qin CJ, Zhao LH, Zhou X, Cai LL, Wang XZ, Guo WH and Zheng JF: The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation. Cell Death Dis 9: 232, 2018.

45. Gantsev SK, Umezawa K, Islamgulov DV, Khusnutdinova EK, Kim M, Rooper L, Xie J, Rayahin J, Burdette JE, Wang T, Han S, Wu Z, Han Z, Yan W, Liu T, Wei H, Song D, et al: Anticancer effects of chemokine-directed tumor hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475: 226-230, 2010.

46. Gao Y, Zhou Z, Huang F and Geng XP: Expression of CCR5 in cancer immunotherapy: More than an 'attractive' receptor for T cells. Oncoimmunology 1: 108-106, 2012.

47. Singh SK, Mishra MK, Elloumi IA, Bae S, Lillard JW Jr and Singh R: CCR5/CCL5 axis interaction promotes migratory and invasive of pancreatic cancer cells. Sci Rep 8: 1232, 2018.

48. Singh SK, Mishra MK, Rivers BM, Gordetsky JB, Bae S and Singh R: Biological and clinical significance of the CCR5/CCL5 axis in hepatocellular carcinoma. Cancers (Basel) 12: 883, 2020.

49. Caso K, Hengady N, Breski M, Amedee C, Vlahos I, et al: Xenobiotic-induced CCL5 secretion from macrophages activates hepatic stellate cells. Hepatology 66: 746-757, 2017.

50. González-Martín A, Mira E and Mañes S: CCR5 in cancer immunotherapy: More than an 'attractive' receptor for T cells. Oncoimmunology 1: 108-106, 2012.

51. Chen K, Zhou Q, Peng X, Qu Z and Zhao T: CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. Oncol Lett 16: 1267-1274, 2018.

52. Pasquier J, Gosset M, Geyl Hoaru-Véchot J, Chevrot A, Pocard M, Mirshahi M, Liras R, Rafii A and Touboul C: CCL2/CCL5 secreted by the stroma induce IL-6 and CCL20 gene expression- driven hepatocarcinogenesis via PI3K/Akt pathway activation. Cancer Res 76: 1335-1347, 2016.

53. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Petyel P, et al: CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res 76: 5651-5660, 2016.

54. Qi S, Perrino S, Miao X, Lamarche-Vane N and Brodt P: The chemokine CCL7 regulates invadopodia maturation and MMP-9 mediated collagen degradation in liver-metastatic carcinoma cells. Cancer Lett 483: 98-113, 2020.

55. Chen Q, Chen X, Cai LL, Wang XZ, Guo WH and Zheng JF: The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation. Cell Death Dis 9: 232, 2018.

56. Hirokawa A, Ohihara T, Shimoji Y, Tanaka T, et al: Activation of CCR10 is associated with advanced hepatocellular carcinoma. Mol Cancer Res 14: 1068-1077, 2016.
93. Croker AK and Allan AL: Cancer stem cells: Implications for...
122. Si Y, Kim S, Zhang E, Tang Y, Jaskula-Sztul R, Markert JM, Chen H, Zhou L and Liu XM: Targeted exosomes for drug delivery: Biomanufacturing, surface tagging, and validation. Adv Drug Deliv Rev 176: 104163, 2023.

123. Prada I and Meldolesi J: Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. Int J Mol Sci 17: 1296, 2016.

124. Nakase and Futaki S: Combined treatment with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of siRNA. Nucleic Acids Res 35: 10112, 2015.

125. Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P and Schifferles RM: Display of GPI-anchored anti-EGF-R nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracellular Vesicles 5: 31053, 2016.

126. Prada I and Meldolesi J: Binding and fusion of extracellular vesicles promotes tumour cell targeting. J Extracellular Vesicles 5: 31053, 2016.

127. Lu YC, Yeh CT and Lin KH: Cancer stem cell functions in hepatocellular carcinoma. Hepatol Res 40: 424-431, 2010.

128. Bai H, Weng Y, Bai S, Jiang Y, Li B, He F, Zhang R, Yan S, Deng F, Wang J and Shi Q: CCL5 secreted from bone marrow stromal cells stimulates the migration of HCC-derived hepatocellular carcinoma cells via the PI3K-Akt pathway. Int J Oncol 43: 333-343, 2014.

129. Liao WC, Yen HR, Liao CK, Tseng TJ, Lan CT and Liu CH: DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCLR1 axis. Am J Cancer Res 9: 347-362, 2019.

130. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Liu XB, Ma YY, Yeung WH, et al: Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol 60: 103-109, 2014.

131. Zhang Y, Zhao W, Li S, Lv M, Yang X, Li M and Zhang Z: CXCL11 promotes self-renewal and tumorigenicity of CD133+ liver tumor-initiating cells via CXCL3/ERK1/2 signaling. Cancer Lett 449: 163-171, 2019.

132. Lu Y, Liu J, Liu Z, He Y, Zhang Z, Jiang C and Qian Q: Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca. Hepatol Res 40: 17-26, 2020.

133. Lu J, Liu W and Zhang P: CCL15/CXCR1 axis is involved in hepatocellular carcinoma cells migration and invasion. Tumour Biol 37: 4501-4507, 2016.

134. Wei G, Jie Y, Haibo L, Chaoneng W, Dong H, Jianbing Z, Junjie G, Wei G, Jie Y, Haibo L, Chaoneng W, Dong H, Jianbing Z, Junjie G, Lei M, Kang D, Sun X, Liu Y, Wang J and Gao P: The effect of C-C motif chemokine 13 on hepatocellular carcinoma. Hepatol Res 40: 17-26, 2020.

135. Li L, Xu L, Yan J, Zhen ZJ, Ji Y, Liu CQ, Lau WY, Zheng L and Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P and Schifferles RM: Display of GPI-anchored anti-EGF-R nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracellular Vesicles 5: 31053, 2016.

136. Lu Y, Yang Y, Yu P, Tao H, Lu X, Wang L, Liu D, Chen Y and Chen C: Bioinformatics analysis and significance of expression of CC chemokine ligand 23 (CCL23) in hepatocellular carcinoma. Xi Bao Yu Fei Zhen Mian Yi Xue Za Zhi 35: 903-909, 2019 (In Chinese).

137. Xie H, Cui Y, Qin X and Liu Y: Type conversion of secretomes in a 3D TAM2 fibrosarcoma model. Cells 9: 1331, 2020.

138. Huang XW, Fan J and Zhou J: Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. J Exp Clin Cancer Res 34: 129, 2015.

139. Zhao Q, Zhao R, Liu K, Hao M, Zheng R, Zhang C, Wu Y, Zhang X, Li N, Zheng J and Chen D: Radiofrequency ablation-induced CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by increasing chemokine receptor expression and promoting angiogenesis. Scientific Reports 16: 1093, 2020.

140. Liao WC, Yen HR, Liao CK, Tseng TJ, Lan CT and Liu CH: DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCLR1 axis. Am J Cancer Res 9: 347-362, 2019.

141. Chen C: Bioinformatics analysis and significance of expression of CC chemokine ligand 23 (CCL23) in hepatocellular carcinoma. Xi Bao Yu Fei Zhen Mian Yi Xue Za Zhi 35: 903-909, 2019 (In Chinese).

142. Ouyang Y, Liu K, Hao M, Zheng R, Zhang C, Wu Y, Zhang X, Li N, Zheng J and Chen D: Radiofrequency ablation-induced CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by increasing chemokine receptor expression and promoting angiogenesis. Scientific Reports 16: 1093, 2020.